Frontlight ResearchEarly access
Taking peoplePhase 3
ASPIC - Antimicrobial Stewardship for Ventilator Associated Pneumonia in Intensive Care
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- France24 sites in 1 countryChoose a country to see its sites
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 590 people, planned
- Started
- 20 Sept 2022
- Planned end
- 20 Jan 2026
- Type of study
- Interventional
- Record updated
- 23 July 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 15 criteriaShow less
Who can take part
- Adult patient is ≥18
- Diagnosis of microbiologically confirmed of first episode of VAP
- Initial appropriate antibiotic therapy (whether empirical or not); Written informed consent from the patient or a legal representative if appropriate. If absence of a legal representative the patient may be included in emergency procedure; Definitive diagnosis of VAP (in agreement with international guidelines) is defined by association: - Patient under MV>48 hours at the time of the microbiological sampling - New pulmonary infiltrate of which an infectious origin is strongly suspected - worsening oxygenation - Have the following clinical criteria within the 24 hours prior to the first dose of antibiotic therapy Purulent tracheal secretions And at least 1 of the following : • Documented fever (body temperature >38,3°C) • Hypothermia (body temperature <35°C) • White blood cell (WBC) count >10,000 cells/mm3 or <4,000 cells/mm3 - microbiological criteria (positive quantitative culture of a lower respiratory tract (LRT): bronchoalveolar lavage fluid (BAL) (significant threshold ≥104 colony-forming units/mL) or plugged telescopic catheter (PTC) (significant threshold ≥ 103 colony-forming units/mL) or quantitative endotracheal aspirate (ETA) distal pulmonary secretion samples (significant threshold ≥105 colony-forming units/mL)
Who cannot take part
- Patients requiring extracorporeal oxygen therapy (ECMO), either veno-venous or veno-arterial
- Duration of antibiotic therapy prior to inclusion > 72h (for any reason) appropriate to the germs found in the bacterial documentation of the first episode of VAP
- Patients undergoing immunosuppressive therapy or long term corticotherapy > 0.5 mg/kg
- VAP due to: Pseudomonas aeruginosa, Carbapenem-resistant Acinetobacter spp, Carbapenem-resistant EnterobacteriaceaeBacterial VAP occurring in the context of co-infection of COVID-19 or other viral pneumonia (confirmed by RT-PCR)
- Severely immunocompromised patients (such as congenital immunodeficiency, neutropenia (<1leucocyte/ml or <0.5 neutrophil/ml) or acute hematologic malignancy or stem cell transplant, HIV infection with CD4 count below 200/mm3)
- Patient under selective decontamination of the digestive tract
- Pregnant women
- No health insurance coverage
- Inclusion in another interventional study concerning empirical antimicrobial strategies
- Moribund (IGS II>80)
- Thoracic trauma with Abbreviated Injury Scale (AIS) thorax 3
- Patients with empyema, necrotizing and abscessed pneumonia
This trial is currently available in France.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The aim of this study is to investigate whether an antimicrobial stewardship for VAP based on daily assessment of clinical cure and antimicrobial discontinuation, if it is obtained, would be non-inferior in terms of all-cause mortality, treatment failure or occurrence of new episode of VAP
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Record updated
- 23 July 2026